Form 4: Regeneron Director Arthur F. Ryan Acquires Stock and Options

Director Arthur F. Ryan reports acquisition of Regeneron stock and options on January 2, 2025.

Summary

• On January 2, 2025, Arthur F. Ryan, a director of Regeneron Pharmaceuticals, acquired 166 shares of common stock at $0.00 per share.
• Following this transaction, Ryan directly owns 17,748 shares of Regeneron common stock.
• Ryan also acquired 1,958 non-qualified stock options with an exercise price of $719.37.
• These options become exercisable in portions starting from the date of the Issuer's first annual meeting of shareholders following the date of grant, with the remainder becoming exercisable on the first anniversary of the date of grant, and expire on January 2, 2035.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a standard disclosure of stock and option acquisition by a director. The acquisition itself is a positive sign, but the filing is routine.

Positives

• The acquisition of stock and options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

Form 4 filings are routine disclosures for corporate insiders and provide transparency into their transactions in the company's securities.

Stakeholder Impact

• The acquisition of shares and options by a director can positively influence shareholder sentiment.

Key Dates